Loading…
Based on limited metadata, this FDA Warning Letter issued to Acella Pharmaceuticals, LLC on August 14, 2020 concerns drug manufacturing or compliance issues, though the specific violations cannot be determined without access to the full letter text. The warning falls under FDA's drug product regulatory authority, but the issuing office and exact number of violations are not specified in the available metadata. This letter indicates the agency identified concerns serious enough to warrant formal regulatory action against the pharmaceutical manufacturer. Additional review of the complete warning letter would be necessary to identify the specific manufacturing, labeling, or other compliance deficiencies cited.